Skip to main content

View full-text article in PMC

. 2023 Dec 20;37(1):81–97. doi: 10.1021/acs.chemrestox.3c00316

Table 3. Predictions of Endocrine Toxicity Using the VEGA Platform^a.

substance	ER relative binding affinity	ER-mediated effect	AR-mediated effect	TR alpha effect	TR beta effect
DGSM	active^b	inactive^c	inactive^c	inactive^d	inactive^d
MA1 → MA4	active^b	inactive^d	inactive^c	inactive^d	inactive^d
MB1 → MB6	active^b	inactive^d	inactive^c	inactive^d	inactive^d
MB7 → MB8	inactive^c	inactive^d	inactive^c	inactive^d	inactive^d
MB9 → MB16	active^b	inactive^d	inactive^c	inactive^d	inactive^d
MB17→MB20	active^b	inactive^d	inactive^c	inactive^d	inactive^d
MB27	active^b	inactive^d	inactive^c	inactive^d	inactive^d
MC1 → MC4	active^b	inactive^d	inactive^c	inactive^d	inactive^d
MC5 → MC14	inactive^b	inactive^d	inactive^c	inactive^d	inactive^d
MC15 → MC18	inactive^b	inactive^b	inactive^b	inactive^c	inactive^c
MD1 → MD8	active^b	inactive^d	inactive^c	inactive^d	inactive^d
MD9 → MD16	inactive^c	inactive^d	inactive^c	inactive^d	inactive^d

^a

Metabolites identified with IRIS are MA3, MB27, MC1-4, and MD14-15.

^b

Low reliability.

^c

Moderate reliability.

^d

Good reliability.